We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.
- Authors
Lan, Qiaoshuai; Chan, Jasper Fuk-Woo; Xu, Wei; Wang, Lijue; Jiao, Fanke; Zhang, Guangxu; Pu, Jing; Zhou, Jie; Xia, Shuai; Lu, Lu; Yuen, Kwok-Yung; Jiang, Shibo; Wang, Qian
- Abstract
Our previous studies have shown that cholesterol-conjugated, peptide-based pan-coronavirus (CoV) fusion inhibitors can potently inhibit human CoV infection. However, only palmitic acid (C16)-based lipopeptide drugs have been tested clinically, suggesting that the development of C16-based lipopeptide drugs is feasible. Here, we designed and synthesized a C16-modified pan-CoV fusion inhibitor, EK1-C16, and found that it potently inhibited infection by SARS-CoV-2 and its variants of concern (VOCs), including Omicron, and other human CoVs and bat SARS-related CoVs (SARSr-CoVs). These results suggest that EK1-C16 could be further developed for clinical use to prevent and treat infection by the currently circulating MERS-CoV, SARS-CoV-2 and its VOCs, as well as any future emerging or re-emerging coronaviruses.
- Subjects
SARS-CoV-2 Omicron variant; CORONAVIRUS diseases; COVID-19; SARS-CoV-2; PALMITIC acid; MERS coronavirus; INFECTION
- Publication
Viruses (1999-4915), 2022, Vol 14, Issue 3, p549
- ISSN
1999-4915
- Publication type
Article
- DOI
10.3390/v14030549